...
首页> 外文期刊>Journal of ocular pharmacology and therapeutics: The official journal of the Association for Ocular Pharmacology and Therapeutics >Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation.
【24h】

Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation.

机译:超声乳化和人工晶状体植入后,评估0.4%酮咯酸三甲胺眼药水与0.5%酮咯酸三甲胺眼药水。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The aim of this study was to compare the effectiveness and patient tolerance of 0.4% ketorolac tromethamine ophthalmic solution and 0.5% ketorolac tromethamine ophthalmic solution after routine phacoemulsification and lens implantation. Setting: The setting for this study was the Storm Eye Institute and Magill Research Center for Vision Correction, Medical University of South Carolina (Charleston, SC). METHODS: This work was a prospective, double-masked study that included 40 eyes of 40 patients randomly assigned to receive topical treatment with 0.4% ketorolac or 0.5% ketorolac, starting 15 min prior to routine phacoemulsification and foldable posterior chamber intraocular lens implantation. Following the procedure, patients were instructed to use the assigned treatment agent 4 times a day after surgery for 1 week and twice a day for 3 weeks, when drops were discontinued. Slit-lamp examination, intraocular pressure (IOP), laser cell and flare measurements, and subjective patient tolerance were evaluated postoperatively at 1, 7, and 30 d. Comparisons between the 2 groups were made at each visit, as well as comparisons to baseline. A P=value less than .05 was considered statistically significant. RESULTS: At day 1, a higher percentage of patients (70% vs. 40%) reported symptoms (mainly foreign body sensation and stinging/burning) in the 0.5% ketorolac group, compared to the 0.4% ketorolac group. No significant differences were found between the 2 groups over time regarding best-corrected visual acuity (BCVA), IOP, slit-lamp assessment of cells, and cell and flare measured using the laser cell/flare meter. CONCLUSIONS: Treatment with 0.4% ketorolac tromethamine ophthalmic solution is as effective as 0.5% ketorolac tromethamine ophthalmic solution in reducing inflammation after routine cataract surgery. Patients reported less discomfort using 0.4% ketorolac.
机译:目的:本研究的目的是比较常规超声乳化和晶状体植入后0.4%酮咯酸三甲胺眼药水和0.5%酮咯酸三甲胺眼药水的有效性和患者耐受性。地点:这项研究的地点是南卡罗来纳州医科大学(南卡罗来纳州查尔斯顿)的风暴眼研究所和麦吉尔视力矫正研究中心。方法:这项工作是一项前瞻性,双盲研究,包括40名随机分配接受0.4%酮咯酸或0.5%酮咯酸局部治疗的患者的40只眼,从常规超声乳化术和可折叠后房型人工晶状体植入术开始前15分钟开始。遵循该程序,患者被告知在手术后每天4次使用指定的治疗剂,持续1周,每天两次,持续3周,这时停药了。术后1、7和30 d评估裂隙灯检查,眼压(IOP),激光细胞和耀斑测量以及主观患者耐受性。每次访视时对两组进行比较,并与基线进行比较。 P =小于0.05的值被认为具有统计学意义。结果:在第1天,与0.4%的酮咯酸组相比,有0.5%的酮咯酸组患者出现症状(主要是异物感和刺痛/灼伤)的比例更高(70%比40%)。随时间推移,两组之间在最佳矫正视敏度(BCVA),IOP,裂隙灯评估细胞以及使用激光细胞/耀斑仪测量的细胞和耀斑方面均未发现显着差异。结论:在常规白内障手术后,用0.4%酮咯酸三甲胺眼药水治疗与减少0.5%酮咯酸三甲胺眼药水治疗效果相同。患者报告使用0.4%酮咯酸的不适感较小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号